Pfizer to Buy ReViral for $525 Million

(PLX AI) – Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates for total consideration of up to $525 million.ReViral is a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, …